Glucose Biosensors Market - Databook 2025 to 2034

The global glucose biosensors market size was estimated at USD 16.66 billion in 2024 and is projected to be worth around USD 57.11 billion by 2034, growing at a CAGR of 13.11% from 2025 to 2034.

Highlights of the Glucose Biosensors Market

• North America dominated the global glucose biosensors market by holding a sizeable portion of the market share in 2024.
• Asia Pacific is expected to grow at a notable CAGR of 5% from 2025 to 2034.
• By type, the self-monitoring blood glucose segment held the major glucose biosensors market share in 2024.
• By type, the continuous glucose monitoring segment is projected to grow at a CAGR between 2025 and 2034.
• By technology, the electrochemical biosensors segment contributed the biggest glucose biosensors market share in 2024.
• By technology, the optical biosensors segment is expanding at a significant CAGR of in between 2025 and 2034.
• By end-use, the home care centers segment dominated the glucose biosensors market in 2024.
• By end-use, the hospitals segment is expected to grow at a significant CAGR over the projected period.

Industry Valuation and Growth Rate Projection

Glucose biosensors for SMBG are generally based on the two enzyme families, GOx and GDH. The enzymes differ in selectivity, turnover rate, cofactors, and redox potentials for glucose. GOx is the standard enzyme for biosensors, and it has a relatively higher selectivity for glucose. The sensor is a tiny piece of material that measures a real-time glucose level in your intestinal fluid. Glucose biosensors are highly used in clinical applications for the diagnosis of diabetes mellitus, which requires precise control over blood glucose levels. Advanced technologies in glucose biosensor devices, increasing government initiatives to generate diabetes awareness, and rising demand for self-monitoring devices worldwide are driving the growth of the glucose biosensors market.

• According to a report published by the International Diabetes Federation, 590 million people worldwide had diabetes in 2024. The total number of people living with diabetes is projected to rise to 853 million by 2050.

Glucose Biosensors: Stats and Figures

• According to a report published by the World Health Organization (WHO), about 830 million people worldwide have diabetes, the majority living in low- and middle-income countries.
• In February 2025, a ground-breaking approach to diabetes management, with the development of non-invasive glucose biosensors made from natural egg white, was developed by University of Manitoba (UM) researchers.

How has AI Benefited the Glucose Biosensors Market?

Artificial intelligence (AI) applications in healthcare are highly powerful in diabetes management. By using data from the patient histories, wearables, and continuous glucose monitors, AI models in healthcare can recommend timely interventions, analyze trends, and predict blood glucose fluctuations. AI is a powerful adjunct that is increasingly influencing CGM (continuous glucose monitoring) data interpretation. The use of AI in diabetes care has focused on early intervention and treatment management. AI improves security monitoring by constantly analyzing network traffic and user behavior to detect anomalies that may indicate a security breach.

Industry Leader Announcements

• The lead authors of studies, David Nathanson, MD, PhD, Karolinska University Hospital in Sweden

One of the lead authors of studies, David Nathanson, MD, PhD, Karolinska University Hospital in Sweden, said, “These results are remarkable, as we see dual benefits from CGM technology in managing diabetes and its associated cardiovascular complications.”

• Kevin Sayer, chairman, president, and chief executive officer at Dexcom

“Jon has demonstrated the ability to lead organizations through the complexities of global healthcare with consistently strong performance across a variety of sectors and channels,” said Kevin Sayer, chairman, president, and chief executive officer at Dexcom. “This broad experience across market segments and regions provides a great fit as we look to capitalize on Dexcom’s incredible growth opportunity.”

Geographical Insights

North America dominated the global glucose biosensors market by holding more than 5% market share in 2024. Advanced technologies in glucose biosensor devices, rising government initiatives to increase awareness regarding diabetes, and increasing demand for self-monitoring devices are driving the growth of the market in glucose biosensor market.

Asia Pacific is expected to grow at a notable CAGR of 5% from 2025 to 2034. Regulatory support, technological advancements, and rising demand are driving the growth of the glucose biosensors market. According to a report published by India Science, Technology & Innovation on glucose biosensors, the device is compact and user-friendly, and it can be efficiently used in bedside diagnosis, diabetes monitoring, pre- and post-prandial glucose levels, and many more.

Recent Developments in the Glucose Biosensors Market

• In December 2024, the First Generative AI Platform in Glucose Biosensing was launched by the global leader in glucose biosensing, DexCom, Inc.
• In September 2024, Lingo's over-the-counter continuous glucose monitoring (CGM) system will be available without a prescription in the U.S., as announced by Abbott Laboratories.

Competitive Landscape

• Company Name: Abbott Laboratories
• Year of Incorporation: 1894
• Headquarters: Chicago, Illinois, United States

Over 75 countries where it operates. It operates in the healthcare and medical devices sector, which helps to improve healthcare around the world.

• Company Name: DexCom
• Year of Incorporation: 1999
• Headquarters: San Diego, California, United States

This company operates in over 160 countries. It operates in medical devices, nutritional products, diagnostic products, branded generic medicines, and pharmaceutical products.